Clinical trial

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

NCT03320031

Study summary

ClinicalTrials.gov

A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy

Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE4

Loading study purpose, treatment groups and outcomes…

View the complete registry record, eligibility and contacts at ClinicalTrials.gov

Drugs and interventions used in this trial

2 registered

These interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.

DRUG · Mapped RxNorm record Linagliptin Normalized identity: linagliptin View linked drug · Find medicine records · Find other trials using this name

DRUG · Unmapped registry intervention Humalog Mix 75/25 Find medicine records · Find other trials using this name

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2017-06-03

PhasePHASE4

Conditions

Type 2 Diabetes Mellitusverified · MONDO: type 2 diabetes mellitus

Peritoneal Dialysisunresolved

Interventions

LinagliptinDRUG · verified · RxNorm: linagliptin

Humalog Mix 75/25DRUG

Sponsors & collaborators

Yanbing Lilead sponsor

Mapped research locations

GuangzhouGuangdong, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03320031 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.